Hans Garmo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1044114/publications.pdf

Version: 2024-02-01

152	4,637	87723	123241
papers	citations	38 h-index	61 g-index

155	155	155	6929
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Mortality in men with castrationâ€resistant prostate cancerâ€”A longâ€term followâ€up of a populationâ€based realâ€world cohort. BJUI Compass, 2022, 3, 173-183.	0.7	12
2	Time on treatment with abiraterone in men with de novo metastatic castration sensitive prostate cancer: a drug utilization study. Acta OncolÃ³gica, 2022, 61, 328-332.	0.8	3
3	Population-based estimates of age and comorbidity specific life expectancy: a first application in Swedish males. BMC Medical Informatics and Decision Making, 2022, 22, 35.	1.5	8
4	Satisfaction with Nurse-led Follow-up in Prostate Cancer Patientsâ€”A Nationwide Population-based Study. European Urology Open Science, 2022, 38, 25-31.	0.2	2
5	Androgen deprivation therapy, comorbidity, cancer stage and mortality from COVID-19 in men with prostate cancer. Scandinavian Journal of Urology, 2022, 56, 104-111.	0.6	9
6	Abstract P3-20-02: The association of clinicopathological variables and patientÂ´s preference with surgical decision-making for early breast cancer. Cancer Research, 2022, 82, P3-20-02-P3-20-02.	0.4	0
7	Qualitative Analysis of Interviews and Focus Groups Exploring Factors Contributing to Adherence to GnRH Agonists in Men with Prostate Cancer. Seminars in Oncology Nursing, 2022, 38, 151236.	0.7	2
8	Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonists. Scandinavian Journal of Urology, 2022, 56, 169-175.	0.6	1
9	Susceptibility to <scp>SARSâ€Cov</scp>â€2 infection and risk for severe <scp>COVID</scp>â€19 in patients with prostate cancer on androgen deprivation therapy. International Journal of Cancer, 2022, 151, 1925-1934.	2.3	2
10	Risk of cardiovascular disease following gonadotropinâ€releasing hormone agonists vs antagonists in prostate cancer: Realâ€world evidence from five databases. International Journal of Cancer, 2021, 148, 2203-2211.	2.3	19
11	Simulation model of disease incidence driven by diagnostic activity. Statistics in Medicine, 2021, 40, 1172-1188.	0.8	4
12	The Value of Real-World Data in Understanding Prostate Cancer Risk and Improving Clinical Care: Examples from Swedish Registries. Cancers, 2021, 13, 875.	1.7	6
13	Risk of cardiovascular events in men on abiraterone or enzalutamide combined with GnRH agonists: nation-wide, population-based cohort study in Sweden. Acta OncolÃ³gica, 2021, 60, 459-465.	0.8	7
14	Short-term ciprofloxacin prophylaxis for prostate biopsy and risk of aortic aneurysm. Nationwide, population-based cohort study. Scandinavian Journal of Urology, 2021, 55, 221-226.	0.6	5
15	An Aggregated Comorbidity Measure Based on History of Filled Drug Prescriptions: Development and Evaluation in Two Separate Cohorts. Epidemiology, 2021, 32, 607-615.	1.2	19
16	Variation in Prostate-Specific Antigen Testing Rates and Prostate Cancer Treatments and Outcomes in a National 20-Year Cohort. JAMA Network Open, 2021, 4, e219444.	2.8	5
17	Temporal changes in causeâ€specific death in men with localised prostate cancer treated with radical prostatectomy: a populationâ€based, nationwide study. Journal of Surgical Oncology, 2021, 124, 867-875.	0.8	1
18	Risk of primary lung cancer after adjuvant radiotherapy in breast cancerâ€”a large population-based study. Npj Breast Cancer, 2021, 7, 71.	2.3	10

#	Article	IF	Citations
19	A drug comorbidity index to predict mortality in men with castration resistant prostate cancer. PLoS ONE, 2021, 16, e0255239.	1.1	3
20	Time on treatment with abiraterone and enzalutamide in the Patient-overview Prostate Cancer in The National Prostate Cancer Register of Sweden. Acta OncolÃ³gica, 2021, 60, 1589-1596.	0.8	3
21	Association between serum markers of the humoral immune system and inflammation in the Swedish AMORIS study. BMC Immunology, 2021, 22, 61.	0.9	7
22	Data Resource Profile: Breast Cancer Data Base Sweden (BCBaSe 2.0). International Journal of Epidemiology, 2021, , .	0.9	3
23	Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study. Breast, 2021, 59, 157-164.	0.9	18
24	Androgen deprivation therapy and excess mortality in men with prostate cancer during the initial phase of the COVID-19 pandemic. PLoS ONE, 2021, 16, e0255966.	1.1	18
25	Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study. BMC Cancer, 2021, 21, 1259.	1.1	1
26	Temporal changes in survival in men with de novo metastatic prostate cancer: nationwide population-based study. Acta OncolÃ³gica, 2020, 59, 106-111.	0.8	12
27	No generally increased risk of cancer after total hip arthroplasty performed due to osteoarthritis. International Journal of Cancer, 2020, 147, 76-83.	2.3	7
28	Predicting Prostate Cancer Death with Different Pretreatment Risk Stratification Tools: A Head-to-head Comparison in a Nationwide Cohort Study. European Urology, 2020, 77, 180-188.	0.9	87
29	Long-term adherence to GnRH agonists in men with prostate cancer. A nation-wide population-based study in prostate cancer data base Sweden. Scandinavian Journal of Urology, 2020, 54, 20-26.	0.6	11
30	PSA testing patterns in a large Swedish cohort before the implementation of organized PSA testing. Scandinavian Journal of Urology, 2020, 54, 376-381.	0.6	10
31	Use of Warfarin or Direct Oral Anticoagulants and Risk of Prostate Cancer in PCBaSe: A Nationwide Case-Control Study. Frontiers in Oncology, 2020, 10, 571838.	1.3	4
32	Adherence to guidelines for androgen deprivation therapy after radical prostatectomy: Swedish population-based study. Scandinavian Journal of Urology, 2020, 54, 208-214.	0.6	6
33	Comparative Effectiveness of Different Radical Radiotherapy Treatment Regimens for Prostate Cancer: A Population-Based Cohort Study. JNCI Cancer Spectrum, 2020, 4, pkaa006.	1.4	5
34	Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: a population-based case-control study. BMC Cancer, 2020, 20, 551.	1.1	10
35	Serum Immunoglobulin G Is Associated With Decreased Risk of Pancreatic Cancer in the Swedish AMORIS Study. Frontiers in Oncology, 2020, 10, 263.	1.3	7
36	Radical radiotherapy for prostate cancer: patterns of care in Sweden 1998â€“2016. Acta OncolÃ³gica, 2020, 59, 549-557.	0.8	11

#	Article	IF	Citations
37	Spironolactone use is associated with lower prostate cancer risk: a population-wide case-control study. Prostate Cancer and Prostatic Diseases, 2020, 23, 527-533.	2.0	14
38	Long-term risk of ischemic heart disease after adjuvant radiotherapy in breast cancer: results from a large population-based cohort. Breast Cancer Research, 2020, 22, 10.	2.2	29
39	Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason Grade: Nationwide, population-based register study. PLoS ONE, 2020, 15, e0228447.	1.1	23
40	Changes in treatment and mortality in men with locally advanced prostate cancer between 2000 and 2016: a nationwide, populationâ€based study in Sweden. BJU International, 2020, 126, 142-151.	1.3	12
41	5Î±-Reductase Inhibitors and Risk of Prostate Cancer Death. Journal of Urology, 2020, 204, 714-719.	0.2	8
42	Prescription-based prediction of baseline mortality risk among older men. PLoS ONE, 2020, 15, e0241439.	1.1	12
43	Observational study on time on treatment with abiraterone and enzalutamide. PLoS ONE, 2020, 15, e0244462.	1.1	8
44	Title is missing!. , 2020, 15, e0228447.		0
45	Title is missing!. , 2020, 15, e0228447.		0
46	Title is missing!. , 2020, 15, e0228447.		0
47	Title is missing!. , 2020, 15, e0228447.		0
48	Prescription-based prediction of baseline mortality risk among older men. , 2020, 15, e0241439.		0
49	Prescription-based prediction of baseline mortality risk among older men. , 2020, 15, e0241439.		0
50	Prescription-based prediction of baseline mortality risk among older men. , 2020, 15, e0241439.		0
51	Prescription-based prediction of baseline mortality risk among older men. , 2020, 15, e0241439.		0
52	Metabolic profiles to predict long-term cancer and mortality: the use of latent class analysis. BMC Molecular and Cell Biology, 2019, 20, 28.	1.0	4
53	Chronic inflammation markers are associated with risk of pancreatic cancer in the Swedish AMORIS cohort study. BMC Cancer, 2019, 19, 858.	1.1	30
54	Chronic inflammatory diseases, anti-inflammatory medications and risk of prostate cancer: a population-based case-control study. BMC Cancer, 2019, 19, 612.	1.1	9

#	Article	IF	Citations
55	How to measure temporal changes in care pathways for chronic diseases using health care registry data. BMC Medical Informatics and Decision Making, 2019, 19, 103.	1.5	3
56	Baseline serum folate, vitamin B12 and the risk of prostate and breast cancer using data from the Swedish AMORIS cohort. Cancer Causes and Control, 2019, 30, 603-615.	0.8	15
57	The relationship between radiation doses to coronary arteries and location of coronary stenosis requiring intervention in breast cancer survivors. Radiation Oncology, 2019, 14, 40.	1.2	74
58	Survival after radiotherapy versus radical cystectomy for primary muscleâ€invasive bladder cancer: A Swedish nationwide populationâ€based cohort study. Cancer Medicine, 2019, 8, 2196-2204.	1.3	12
59	Realâ€world insights into risk of developing cardiovascular disease following Gn<scp>RH</scp> agonists versus antagonists for prostate cancer: a methodological protocol to a study using five European databases. Fundamental and Clinical Pharmacology, 2019, 33, 479-499.	1.0	3
60	Serum glucose, triglycerides, and cholesterol in relation to prostate cancer death in the Swedish AMORIS study. Cancer Causes and Control, 2019, 30, 195-206.	0.8	14
61	Androgen deprivation therapy for prostate cancer and risk of dementia. BJU International, 2019, 124, 87-92.	1.3	26
62	Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational study. Acta OncolÃ³gica, 2019, 58, 110-118.	0.8	4
63	Mortality after radical prostatectomy in a matched contemporary cohort in Sweden compared to the Scandinavian Prostate Cancer Group 4 (<scp>SPCG</scp>â€4) study. BJU International, 2019, 123, 421-428.	1.3	14
64	Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer. European Urology, 2019, 75, 676-683.	0.9	12
65	Prostate Cancer Death After Radiotherapy or Radical Prostatectomy: A Nationwide Population-based Observational Study. European Urology, 2018, 73, 502-511.	0.9	37
66	Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study. BMJ Open, 2018, 8, e020787.	0.8	8
67	Association between type 2 diabetes, curative treatment and survival in men with intermediateâ€and highâ€risk localized prostate cancer. BJU International, 2018, 121, 209-216.	1.3	4
68	Drugs for metabolic conditions and prostate cancer death in men on Gn<scp>RH</scp> agonists. BJU International, 2018, 121, 260-267.	1.3	3
69	The use of palliative medications before death from prostate cancer: Swedish population-based study with a comparative overview of European data. European Journal of Cancer, 2018, 88, 101-108.	1.3	10
70	A systematic review of the literature exploring the interplay between prostate cancer and type two diabetes mellitus. Ecancermedicalscience, 2018, 12, 802.	0.6	19
71	Can pre-diagnostic serum levels of sodium and potassium predict prostate cancer survival?. BMC Cancer, 2018, 18, 1169.	1.1	5
72	Radical Prostatectomy or Watchful Waiting in Prostate Cancer â€" 29-Year Follow-up. New England Journal of Medicine, 2018, 379, 2319-2329.	13.9	338

#	Article	IF	Citations
73	Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study. Leukemia Research, 2018, 74, 105-109.	0.4	13
74	Satisfaction with Care Among Men with Localised Prostate Cancer: A Nationwide Population-based Study. European Urology Oncology, 2018, 1, 37-45.	2.6	16
75	Glucose, lipids and gamma-glutamyl transferase measured before prostate cancer diagnosis and secondly diagnosed primary tumours: a prospective study in the Swedish AMORIS cohort. BMC Cancer, 2018, 18, 205.	1.1	3
76	H eterogeneity in risk of prostate cancer: A S wedish populationâ€based cohort study of competing risks and T ype 2 diabetes mellitus. International Journal of Cancer, 2018, 143, 1868-1875.	2.3	9
77	A case-control study of lower urinary-tract infections, associated antibiotics and the risk of developing prostate cancer using PCBaSe 3.0. PLoS ONE, 2018, 13, e0195690.	1.1	6
78	Thyroid cancer risk in the Swedish AMORIS study: the role of inflammatory biomarkers in serum. Oncotarget, 2018, 9, 774-782.	0.8	7
79	Cancer Specific Mortality in Men Diagnosed with Prostate Cancer before Age 50 Years: A Nationwide Population Based Study. Journal of Urology, 2017, 197, 61-66.	0.2	34
80	Re: Adi J. Klil-Drori, Hui Yin, Vicky Tagalakis, Armen Aprikian, Laurent Azoulay. Androgen Deprivation Therapy for Prostate Cancer and Risk of Venous Thromboembolism. Eur Urol 2016;70:56â€“61. European Urology, 2017, 71, e61-e62.	0.9	0
81	The association between individual metabolic syndrome components, primary liver cancer and cirrhosis: A study in the Swedish AMORIS cohort. International Journal of Cancer, 2017, 141, 1148-1160.	2.3	53
82	Serum inflammatory markers and colorectal cancer risk and survival. British Journal of Cancer, 2017, 116, 1358-1365.	2.9	61
83	Prostate Cancer Radiation Therapy and Risk of Thromboembolic Events. International Journal of Radiation Oncology Biology Physics, 2017, 97, 1026-1031.	0.4	9
84	The Influence of Preoperative Symptoms on the Death of Patients with Small Intestinal Neuroendocrine Tumors. Annals of Surgical Oncology, 2017, 24, 1214-1220.	0.7	14
85	Cohort profile: The Swedish National Register of Urinary Bladder Cancer (SNRUBC) and the Bladder Cancer Data Base Sweden (BladderBaSe). BMJ Open, 2017, 7, e016606.	0.8	44
86	Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based Study. European Urology, 2017, 72, 920-928.	0.9	21
87	Glucose and lipoprotein biomarkers and breast cancer severity using data from the Swedish AMORIS cohort. BMC Cancer, 2017, 17, 246.	1.1	12
88	Circulating gamma-glutamyl transferase and development of specific breast cancer subtypes: findings from the Apolipoprotein Mortality Risk (AMORIS) cohort. Breast Cancer Research, 2017, 19, 22.	2.2	9
89	Inter-observer variation in delineating the coronary arteries as organs at risk. Radiotherapy and Oncology, 2017, 122, 72-78.	0.3	27
90	Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer. International Journal of Cancer, 2017, 140, 611-617.	2.3	47

#	Article	IF	Citations
91	Quantifying the Transition from Active Surveillance to Watchful Waiting Among Men with Very Low-risk Prostate Cancer. European Urology, 2017, 72, 534-541.	0.9	17
92	Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study. European Urology, 2017, 72, 125-134.	0.9	21
93	Circulating uric acid levels and subsequent development of cancer in 493,281 individuals: findings from the AMORIS Study. Oncotarget, 2017, 8, 42332-42342.	0.8	37
94	Serum biomarkers to predict risk of testicular and penile cancer in AMORIS. Ecancermedicalscience, 2017, 11, 762.	0.6	6
95	Serum Calcium and the Risk of Breast Cancer: Findings from the Swedish AMORIS Study and a Meta-Analysis of Prospective Studies. International Journal of Molecular Sciences, 2016, 17, 1487.	1.8	28
96	Investigating the association between allergen-specific immunoglobulin E, cancer risk and survival. OncoImmunology, 2016, 5, e1154250.	2.1	34
97	Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation therapy. BJU International, 2016, 118, 391-398.	1.3	23
98	Association between serum calcium concentration and risk of incident and fatal cardiovascular disease in the prospective AMORIS study. Atherosclerosis, 2016, 251, 85-93.	0.4	56
99	Proportion and characteristics of men with unknown risk category in the National Prostate Cancer Register of Sweden. Acta OncolÃ³gica, 2016, 55, 1461-1466.	0.8	16
100	Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts. Breast Cancer Research, 2016, 18, 119.	2.2	40
101	Immediate versus delayed prostatectomy: Nationwide population-based study. Scandinavian Journal of Urology, 2016, 50, 246-254.	0.6	22
102	Effect of selective serotonin reuptake inhibitors use on endocrine therapy adherence and breast cancer mortality: a population-based study. Breast Cancer Research and Treatment, 2016, 159, 293-303.	1.1	18
103	Association between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categories. Cancer Medicine, 2016, 5, 1307-1318.	1.3	46
104	Interpretation of conventional survival analysis and competingâ€risk analysis: an example of hypertension and prostate cancer. BJU International, 2016, 118, 850-852.	1.3	9
105	Causes of death in men with localized prostate cancer: a nationwide, populationâ€based study. BJU International, 2016, 117, 507-514.	1.3	43
106	Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer. International Journal of Cancer, 2016, 139, 2698-2704.	2.3	29
107	Long-term outcome in young women with breast cancer: a population-based study. Breast Cancer Research and Treatment, 2016, 160, 131-143.	1.1	82
108	Family History and Probability of Prostate Cancer, Differentiated by Risk Category: A Nationwide Population-Based Study. Journal of the National Cancer Institute, 2016, 108, djw110.	3.0	69

#	Article	IF	Citations
109	Radiation dose distribution in coronary arteries in breast cancer radiotherapy. Acta OncolÃ³gica, 2016, 55, 959-963.	0.8	31
110	Risk of malignant melanoma in men with prostate cancer: Nationwide, population-based cohort study. International Journal of Cancer, 2016, 138, 2154-2160.	2.3	13
111	Cohort Profile Update: The National Prostate Cancer Register of Sweden and Prostate Cancer data Baseâ€"a refined prostate cancer trajectory. International Journal of Epidemiology, 2016, 45, 73-82.	0.9	78
112	Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment. European Urology, 2016, 70, 824-828.	0.9	22
113	Progression of breast cancer following locoregional ipsilateral recurrence: importance of interval time. British Journal of Cancer, 2016, 114, 88-95.	2.9	18
114	Determinants of non-adherence to adjuvant endocrine treatment in early stage breast cancer patients: A Swedish population-based registry linkage study.. Journal of Clinical Oncology, 2016, 34, 535-535.	0.8	0
115	How to model temporal changes in comorbidity for cancer patients using prospective cohort data. BMC Medical Informatics and Decision Making, 2015, 15, 96.	1.5	11
116	Prediagnostic serum glucose and lipids in relation to survival in breast cancer patients: a competing risk analysis. BMC Cancer, 2015, 15, 913.	1.1	22
117	An investigation into the relationship between statins and cancer using population-based data. BJU International, 2015, 116, 681-683.	1.3	5
118	Anabolic steroids and cardiovascular risk: A national population-based cohort study. Drug and Alcohol Dependence, 2015, 152, 87-92.	1.6	86
119	Prediagnostic serum inflammatory markers in relation to breast cancer risk, severity at diagnosis and survival in breast cancer patients. Carcinogenesis, 2015, 36, 1121-1128.	1.3	43
120	Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma. JAMA - Journal of the American Medical Association, 2015, 313, 2449.	3.8	76
121	Risk and Timing of Cardiovascular Disease After Androgen-Deprivation Therapy in Men With Prostate Cancer. Journal of Clinical Oncology, 2015, 33, 1243-1251.	0.8	225
122	Serum lactate dehydrogenase and survival following cancer diagnosis. British Journal of Cancer, 2015, 113, 1389-1396.	2.9	66
123	Risk of Fractures and Falls during and after 5-Î± Reductase Inhibitor Use: A Nationwide Cohort Study. PLoS ONE, 2015, 10, e0140598.	1.1	8
124	Incidence of Second Malignancies for Prostate Cancer. PLoS ONE, 2014, 9, e102596.	1.1	27
125	Patterns of androgen deprivation therapies among men diagnosed with localised prostate cancer: A population-based study. European Journal of Cancer, 2014, 50, 1789-1798.	1.3	17
126	Effect of Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma in Situ: 20 Years Follow-Up in the Randomized SweDCIS Trial. Journal of Clinical Oncology, 2014, 32, 3613-3618.	0.8	184

#	Article	IF	Citations
127	Nationwide Population Based Study of Infections after Transrectal Ultrasound Guided Prostate Biopsy. Journal of Urology, 2014, 192, 1116-1122.	0.2	84
128	Serum calcium and risk of gastrointestinal cancer in the Swedish AMORIS study. BMC Public Health, 2013, 13, 663.	1.2	26
129	Iron metabolism and risk of cancer in the Swedish AMORIS study. Cancer Causes and Control, 2013, 24, 1393-1402.	0.8	51
130	Population-based study on use of chemotherapy in men with castration resistant prostate cancer. Acta OncolÃ³gica, 2013, 52, 1593-1601.	0.8	44
131	Cohort Profile: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. International Journal of Epidemiology, 2013, 42, 956-967.	0.9	194
132	Dietary Patterns and prostate cancer risk: a population based cohort study in elderly Swedish men. FASEB Journal, 2013, 27, 847.8.	0.2	1
133	Tumor Stage Affects Risk and Prognosis of Contralateral Breast Cancer: Results From a Large Swedish-Populationâ€“Based Study. Journal of Clinical Oncology, 2012, 30, 3478-3485.	0.8	46
134	Serum Lipids and the Risk of Gastrointestinal Malignancies in the Swedish AMORIS Study. Journal of Cancer Epidemiology, 2012, 2012, 1-10.	0.5	67
135	Differences according to socioeconomic status in the management and mortality in men with high risk prostate cancer. European Journal of Cancer, 2012, 48, 75-84.	1.3	52
136	Serum calcium and incident and fatal prostate cancer in the Swedish AMORIS study. Cancer Causes and Control, 2012, 23, 1349-1358.	0.8	21
137	The interplay between lipid profiles, glucose, BMI and risk of kidney cancer in the Swedish AMORIS study. International Journal of Cancer, 2012, 130, 2118-2128.	2.3	47
138	Biomarker-based score to predict mortality in persons aged 50 years and older: a new approach in the Swedish AMORIS study. International Journal of Molecular Epidemiology and Genetics, 2012, 3, 66-76.	0.4	24
139	Lipid profiles and the risk of endometrial cancer in the Swedish AMORIS study. International Journal of Molecular Epidemiology and Genetics, 2012, 3, 122-33.	0.4	22
140	Comorbidity, Treatment and Mortality: A Population Based Cohort Study of Prostate Cancer in PCBaSe Sweden. Journal of Urology, 2011, 185, 833-840.	0.2	104
141	Gamma-glutamyltransferase and risk of cancer in a cohort of 545,460 persons â€“ the Swedish AMORIS study. European Journal of Cancer, 2011, 47, 2033-2041.	1.3	83
142	Mortality Among Men with Locally Advanced Prostate Cancer Managed with Noncurative Intent: A Nationwide Study in PCBaSe Sweden. European Urology, 2011, 60, 554-563.	0.9	65
143	Prognosis of metachronous contralateral breast cancer: importance of stage, age and interval time between the two diagnoses. Breast Cancer Research and Treatment, 2011, 130, 609-618.	1.1	37
144	Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study. Cancer Causes and Control, 2011, 22, 1011-1019.	0.8	63

#	Article	IF	Citations
145	Impaired glucose metabolism and diabetes and the risk of breast, endometrial, and ovarian cancer. Cancer Causes and Control, 2011, 22, 1163-1171.	0.8	81
146	Prostate cancer risk in the Swedish AMORIS study. Cancer, 2011, 117, 2086-2095.	2.0	87
147	Risk of prostate cancer is not associated with levels of Câ€reactive protein and other commonly used markers of inflammation. International Journal of Cancer, 2011, 129, 1485-1492.	2.3	39
148	Association between Levels of C-Reactive Protein and Leukocytes and Cancer: Three Repeated Measurements in the Swedish AMORIS Study. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 428-437.	1.1	52
149	Immunoglobulin E and cancer: a meta-analysis and a large Swedish cohort study. Cancer Causes and Control, 2010, 21, 1657-1667.	0.8	49
150	The Metabolic Syndrome and the Risk of Prostate Cancer under Competing Risks of Death from Other Causes. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2088-2096.	1.1	68
151	Absolute and Relative Risk of Cardiovascular Disease in Men With Prostate Cancer: Results From the Population-Based PCBaSe Sweden. Journal of Clinical Oncology, 2010, 28, 3448-3456.	0.8	173
152	PCBaSe Sweden: A register-based resource for prostate cancer research. Scandinavian Journal of Urology and Nephrology, 2009, 43, 342-349.	1.4	54